← Calendar
Readoutin 134d
Boehringer Ingelheim — Nerandomilast
Phase 3 primary completion: A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast.
- Date
- Apr 2027
- Type
- Readout
- Indication
- Idiopathic Pulmonary Fibrosis
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Boehringer Ingelheim
Apr2027
Readoutin 134d
Boehringer Ingelheim — NerandomilastPhase 3 primary completion: A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases.
Dec2026
Readoutin 13d
Boehringer Ingelheim — BI 690517Phase 3 primary completion: EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin).